Cholinesterase inhibitors and memantine for Parkinson's disease dementia and Lewy body dementia: A meta‑analysis

Meng,Yan‑Hong; Wang,Pan‑Pan; Song,Ya‑Xue; Wang,Jian‑Hua

doi:10.3892/etm.2018.7129

Cholinesterase inhibitors and memantine for Parkinson's disease dementia and Lewy body dementia: A meta‑analysis

Authors:
- Yan‑Hong Meng
- Pan‑Pan Wang
- Ya‑Xue Song
- Jian‑Hua Wang
View Affiliations

Affiliations: Department of Graduate School, Hebei Medical University, Shijiazhuang, Hebei 05001, P.R. China, Department of Neurology, Hebei General Hospital, Shijiazhuang, Hebei 050051, P.R. China
Published online on: December 24, 2018 https://doi.org/10.3892/etm.2018.7129
Pages: 1611-1624
Copyright: © Meng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Recently, several randomized controlled trials on the use of cholinesterase inhibitors or memantine as treatments for cognitive impairment in Parkinson's disease (CIND‑PD), Parkinson's disease with dementia (PDD) and dementia with Lewy bodies (DLB) were completed. The present study provided a meta‑analysis of these studies to evaluate the efficacy of cholinesterase inhibitors and memantine on CIND‑PD, PDD and DLB. The Cochrane Library, Pubmed, Embase and Web of Science databases were searched to retrieve eligible studies. As primary efficacy outcomes, cognitive function, global impression, behavioral symptoms and motor function were selected, while falling and adverse events were regarded as safety outcomes. Of note, domain‑specific cognitive function was assessed as a primary efficacy outcome and falling as a safety outcome, which, to the best of our knowledge, has not been studied previously in CIND‑PD, PDD and DLB. A total of 15 trials were included in the present meta‑analysis. The results revealed that treatment with cholinesterase inhibitors resulted in improvements in cognitive function, the clinician's global impression, behavioral symptoms and motor function, in accordance with the results of previous studies. Furthermore, it was revealed that cholinesterase inhibitors had a significant effect on attention, processing speed, executive functions, memory and language; however, they did not improve visuospatial cognition compared with placebos. Memantine had a significant effect on attention, processing speed and executive functions. In addition, cholinesterase inhibitors and memantine did not significantly reduce falling. It was demonstrated that an increased number of adverse events occurred in the pooled cholinesterase inhibitors and memantine group, compared with that in the placebo group (risk ratio (RR)=1.09; 95% confidence interval (CI): 1.04‑1.16; P=0.001); however, in the subgroup analysis, only the rivastigmine group experienced significantly more adverse events than the placebo group (85 vs. 73%; RR=1.18; 95% CI: 1.08‑1.29; P=0.0001), but donepezil and memantine did not produce any significant adverse events. In conclusion, cholinesterase inhibitors and memantine have an effect not only on global cognitive function and motor function, but also on attention, processing speed, executive functions, memory and language. However, careful monitoring of the side effects of rivastigmine may be required. Further clinical trials are required to verify these conclusions.

View Figures

View References

1	Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H and Kragh-Sørensen P: Risk of dementia in Parkinson's disease-A community-based, prospective study. Neurology. 56:730–736. 2001. View Article : Google Scholar : PubMed/NCBI
2	Aarsland D, Zaccai J and Brayne C: A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord. 20:1255–1263. 2005. View Article : Google Scholar : PubMed/NCBI
3	Mueller C, Ballard C, Corbett A and Aarsland D: The prognosis of dementia with Lewy bodies. Lancet Neurol. 16:390–398. 2017. View Article : Google Scholar : PubMed/NCBI
4	Lippa CF, Duda JE, Grossman M, Hurtig HI, Aarsland D, Boeve BF, Brooks DJ, Dickson DW, Dubois B, Emre M, et al: DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology. 68:812–819. 2007. View Article : Google Scholar : PubMed/NCBI
5	Gomperts SN: Lewy body dementias: Dementia with Lewy bodies and Parkinson disease dementia. Continuum (Minneapolis Minn). 22:435–463. 2016.
6	Matsunaga S, Kishi T and Iwata N: Memantine for Lewy body disorders: Systematic review and meta-analysis. Am J Geriatr Psychiatry. 23:373–383. 2015. View Article : Google Scholar : PubMed/NCBI
7	Matsunaga S, Kishi T, Yasue I and Iwata N: Cholinesterase inhibitors for Lewy body disorders: A meta-analysis. Int J Neuropsychopharmacol. 19:pyv0862015. View Article : Google Scholar : PubMed/NCBI
8	Stinton C, McKeith I, Taylor JP, Lafortune L, Mioshi E, Mak E, Cambridge V, Mason J, Thomas A and O'Brien JT: Pharmacological management of Lewy body dementia: A systematic review and meta-analysis. Am J Psychiatry. 172:731–742. 2015. View Article : Google Scholar : PubMed/NCBI
9	Wang HF, Yu JT, Tang SW, Jiang T, Tan CC, Meng XF, Wang C, Tan MS and Tan L: Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: Systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry. 86:135–143. 2015. View Article : Google Scholar : PubMed/NCBI
10	Li Z, Yu Z and Zhang J, Wang J, Sun C, Wang P and Zhang J: Impact of rivastigmine on cognitive dysfunction and falling in Parkinson's disease patients. Eur Neurol. 74:86–91. 2015. View Article : Google Scholar : PubMed/NCBI
11	Gibb WR and Lees AJ: The relevance of the lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 51:745–752. 1988. View Article : Google Scholar : PubMed/NCBI
12	Hughes AJ, Daniel SE, Kilford L and Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 55:181–184. 1992. View Article : Google Scholar : PubMed/NCBI
13	Larsen JP, Dupont E and Tandberg E: Clinical diagnosis of Parkinson's disease. Proposal of diagnostic subgroups classified at different levels of confidence. Acta Neurol Scand. 89:242–251. 1994. View Article : Google Scholar : PubMed/NCBI
14	Litvan I, Bhatia KP, Burn DJ, Goetz CG, Lang AE, McKeith I, Quinn N, Sethi KD, Shults C and Wenning GK; Movement Disorders Society Scientific Issues Committee, : Movement disorders society scientific issues committee report: SIC task force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord. 18:467–486. 2003. View Article : Google Scholar : PubMed/NCBI
15	American Psychiatric Association (APA): Diagnostic and statistical manual of mental disorders. 4th. American Psychiatric Association; Washington, DC: 1994
16	McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, et al: Diagnosis and management of dementia with lewy bodies: Third report of the DLB consortium. Neurology. 65:1863–1872. 2005. View Article : Google Scholar : PubMed/NCBI
17	Higgins JPT, Deeks JJ and Altman DG: Chapter 16: Special topics in statistics. Higgins JPT and Green S: Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration. 2011, http://www.cochrane-handbook.org
18	Higgins JPT, Altman DJ and Sterne JAC: Chapter 8: Assessing risk of bias in included studies. Higgins JPT and Green S: Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration. 2011, http://www.cochrane-handbook.org
19	Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P and Schünemann HJ; GRADE, : Working Group: GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 336:924–926. 2008. View Article : Google Scholar : PubMed/NCBI
20	Mantel N and Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 22:719–748. 1959.PubMed/NCBI
21	Higgins JP, Thompson SG, Deeks JJ and Altman DG: Measuring inconsistency in meta-analyses. BMJ. 327:557–560. 2003. View Article : Google Scholar : PubMed/NCBI
22	Ikeda M, Mori E, Matsuo K, Nakagawa M and Kosaka K: Donepezil for dementia with Lewy bodies: A randomized, placebo-controlled, confirmatory phase III trial. Alzheimers Res Ther. 7:42015. View Article : Google Scholar : PubMed/NCBI
23	Mori E, Ikeda M and Kosaka K: Donepezil-DLB Study Investigators: Donepezil for dementia with Lewy bodies: A randomized, placebo-controlled trial. Ann Neurol. 72:41–52. 2012. View Article : Google Scholar : PubMed/NCBI
24	Aarsland D, Laake K, Larsen JP and Janvin C: Donepezil for cognitive impairment in Parkinson's disease: A randomised controlled study. J Neurol Neurosurg Psychiatry. 72:708–712. 2002. View Article : Google Scholar : PubMed/NCBI
25	Dubois B, Tolosa E, Katzenschlager R, Emre M, Lees AJ, Schumann G, Pourcher E, Gray J, Thomas G, Swartz J, et al: Donepezil in Parkinson's disease dementia: A randomized, double-blind efficacy and safety study. Mov Disord. 27:1230–1238. 2012. View Article : Google Scholar : PubMed/NCBI
26	Leroi I, Brandt J, Reich SG, Lyketsos CG, Grill S, Thompson R and Marsh L: Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry. 19:1–8. 2004. View Article : Google Scholar : PubMed/NCBI
27	Ravina B, Putt M, Siderowf A, Farrar JT, Gillespie M, Crawley A, Fernandez HH, Trieschmann MM, Reichwein S and Simuni T: Donepezil for dementia in Parkinson's disease: A randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry. 76:934–939. 2005. View Article : Google Scholar : PubMed/NCBI
28	McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, Cicin-Sain A, Ferrara R and Spiegel R: Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebo-controlled international study. Lancet. 356:2031–2036. 2000. View Article : Google Scholar : PubMed/NCBI
29	Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, et al: Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med. 351:2509–2518. 2004. View Article : Google Scholar : PubMed/NCBI
30	Mamikonyan E, Xie SX, Melvin E and Weintraub D: Rivastigmine for mild cognitive impairment in Parkinson disease: A placebo-controlled study. Mov Disord. 30:912–918. 2015. View Article : Google Scholar : PubMed/NCBI
31	Wesnes KA, McKeith IG, Ferrara R, Emre M, Del Ser T, Spano PF, Cicin-Sain A, Anand R and Spiegel R: Effects of rivastigmine on cognitive function in dementia with lewy bodies: A randomised placebo-controlled international study using the cognitive drug research computerised assessment system. Dement Geriatr Cogn Disord. 13:183–192. 2002. View Article : Google Scholar : PubMed/NCBI
32	Leroi I, Overshott R, Byrne EJ, Daniel E and Burns A: Randomized controlled trial of memantine in dementia associated with Parkinson's disease. Mov Disord. 24:1217–1221. 2009. View Article : Google Scholar : PubMed/NCBI
33	Aarsland D, Ballard C, Walker Z, Bostrom F, Alves G, Kossakowski K, Leroi I, Pozo-Rodriguez F, Minthon L and Londos E: Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: A double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 8:613–618. 2009. View Article : Google Scholar : PubMed/NCBI
34	Emre M, Tsolaki M, Bonuccelli U, Destée A, Tolosa E, Kutzelnigg A, Ceballos-Baumann A, Zdravkovic S, Bladström A and Jones R; 11018 Study Investigators, : Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: A randomised, double-blind, placebo-controlled trial. Lancet Neurol. 9:969–977. 2010. View Article : Google Scholar : PubMed/NCBI
35	Stubendorff K, Larsson V, Ballard C, Minthon L, Aarsland D and Londos E: Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: A prospective study. BMJ Open. 4:e0051582014. View Article : Google Scholar : PubMed/NCBI
36	Manabe Y, Ino T, Yamanaka K and Kosaka K: Increased dosage of donepezil for the management of behavioural and psychological symptoms of dementia in dementia with Lewy bodies. Psychogeriatrics. 16:202–208. 2016. View Article : Google Scholar : PubMed/NCBI
37	Mori E, Ikeda M, Nakai K, Miyagishi H, Nakagawa M and Kosaka K: Increased plasma donepezil concentration improves cognitive function in patients with dementia with Lewy bodies: An exploratory pharmacokinetic/pharmacodynamic analysis in a phase 3 randomized controlled trial. J Neurol Sci. 366:184–190. 2016. View Article : Google Scholar : PubMed/NCBI
38	Ukai K, Fujishiro H, Iritani S and Ozaki N: Long-term efficacy of donepezil for relapse of visual hallucinations in patients with dementia with Lewy bodies. Psychogeriatrics. 15:133–137. 2015. View Article : Google Scholar : PubMed/NCBI
39	Litvinenko IV, Odinak MM, Mogil'naya VI and Emelin AY: Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial). Neurosci Behav Physiol. 38:937–945. 2008. View Article : Google Scholar : PubMed/NCBI
40	Larsson V, Aarsland D, Ballard C, Minthon L and Londos E: The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia. Int J Geriatr Psychiatry. 25:1030–1038. 2010. View Article : Google Scholar : PubMed/NCBI
41	Emre M, Poewe W, De Deyn PP, Barone P, Kulisevsky J, Pourcher E, van Laar T, Storch A, Micheli F, Burn D, et al: Long-term safety of rivastigmine in parkinson disease dementia: An open-label, randomized study. Clin Neuropharmacol. 37:9–16. 2014.PubMed/NCBI
42	Sherman DS, Mauser J, Nuno M and Sherzai D: The efficacy of cognitive intervention in mild cognitive impairment (MCI): A meta-analysis of outcomes on neuropsychological measures. Neuropsychol Rev. 27:440–484. 2017. View Article : Google Scholar : PubMed/NCBI